The week in pharma: action, reaction and insight – week to November 14
By Barbara Obstoj-Cardwell
Last week saw the end of the bidding war for Metsera, with the company accepting an improved offer from Pfizer and counter bidder Novo Nordisk pulling out. Also on Friday, Merck & Co announced a $9.2 billion bid for Cidara Therapeutics. On the research front, Roche released Phase III results for its fenebrutinib in patients with relapsing multiple sclerosis. Also, Canada’s enGene Holdings revealed encouraging new data for its bladder cancer candidate detalimogene voraplasmid. Kura Oncology and partner Kyowa Kirin last week gained earlier than expected US Food and Drug Administration for their acute myeloid leukemia drug Komzifti (ziftomenib).
Pfizer secures Metsera acquisition, which brings >$5B pipeline potential
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze